

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED.
SECRETARY OF THE SENATE

03 FEB 14 PM 2:1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Canfield & Associates, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported			
Address 801 Pennsylvania Avenue, NW		Suite 625	
City Washington		State/Zip (or Country) DC 20004	
3. Principal Place of Business (if different from line 2)			
City Same		State/Zip (or Country)	
4. Contact Name April Boston		Telephone (202) 661-2100	E-mail (optional) april@canfieldassoc.com
			5. Senate ID # 7997-0010
7. Client Name <input type="checkbox"/> Self Merck & Company			6. House ID # 3359-2007

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$100,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6013 of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____ Date 11/17/2009

Printed Name and Title Anne Canfield - President 1

Registrant Name: Canfield & Associates, Inc.

Client Name: Merck & Company

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

HR 4954, Medicare Modernization and Prescription Drug Act of 2002, Issues related to delivery of outpatient prescription drugs to Medicare beneficiaries

HR 5005, Homeland Security Act of 2002, Issues related to vaccine injury compensation fund.

S. 1135, Medicare Reform Act of 2001, Issues related to structuring a Medicare outpatient prescription drug benefit

S. 2244, Prescription Drug Price Parity for Americans Act, Issues related to permitting commercial importation of prescription drugs from Canada.

S. 2536, Rx Flexibility for States Act, Issues related to amending Social Security Act to permit states to enter rebate agreements to make outpatient prescription drugs available to persons who do not qualify for Medicaid.

S. 2625, Medicare Outpatient Prescription Drug Act of 2002, Issues related to delivery of outpatient prescription drugs to Medicare beneficiaries

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Blauwet, Roger	
Boston, April	
Canfield, Anne	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None



Signature  Date

Printed Name and Title **Anne Canfield - President** I

Registrant Name: Canfield & Associates, Inc.

Client Name: Merck & Company

Item	Description	Data
16	Lobbying Issues	S. 573, A bil to amend the Social Security Act to allow children enrolled in t state's health insurance program to be eligible for benefits under the pediat vaccine distribution program, Issues related to pediatric vaccines
16	Lobbying Issues	S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, Issues re to amending Hatch-Waxman to permit generics earlier entry into the mark
16	Lobbying Issues	Issues related to research and development within genetic nondiscriminatio legislation (e.g., HR 602: Genetic Nondiscrimination in Health and Insuran Employment Act; S. 318: Genetic Nondiscrimination in Health and Insuran Employment Act; S. 382: Genetic Information Nondiscrimination in Health Insurance Act; S. 1995: Genetic Information Nondiscrimination Act of 200

